Jeremy St J Thomas

Summary

Country: UK

Publications

  1. ncbi DCIS and aromatase inhibitors
    J Michael Dixon
    Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    J Steroid Biochem Mol Biol 106:173-9. 2007
  2. ncbi Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK
    Breast Cancer Res 12:R47. 2010
  3. ncbi Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles
    Robert R Kitchen
    School of Physics, University of Edinburgh, 10 Crichton Street, Edinburgh, EH8 9AB, UK
    BMC Genomics 11:134. 2010
  4. ncbi Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project
    J Thomas
    Pathology Department, Western General Hospital and Breakthrough Breast Cancer Research Unit, Edinburgh EH4 2XU, UK
    Br J Cancer 102:285-93. 2010
  5. ncbi Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring
    J S J Thomas
    Pathology Department, Western General Hospital, Edinburgh, UK
    Histopathology 51:219-26. 2007
  6. ncbi Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project
    Jeremy Thomas
    Department of Pathology, Western General Hospital, Edinburgh, United Kingdom
    Breast J 14:33-8. 2008
  7. ncbi Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up
    Jeremy St J Thomas
    Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
    Histopathology 55:724-31. 2009
  8. ncbi Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
    Matthew J Ellis
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Oncol 24:3019-25. 2006
  9. ncbi Is a radiotherapy boost truly beneficial?
    Alison Stillie
    Lancet Oncol 7:795-6; author reply 796-7. 2006
  10. ncbi Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial
    John M S Bartlett
    Endocrine Cancer Research Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
    J Clin Oncol 26:5027-35. 2008

Collaborators

Detail Information

Publications10

  1. ncbi DCIS and aromatase inhibitors
    J Michael Dixon
    Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    J Steroid Biochem Mol Biol 106:173-9. 2007
    ..68; p<0.001). This study has shown significant effects of aromatase inhibitors on DCIS indicating that these agents are therapeutically active in this condition...
  2. ncbi Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK
    Breast Cancer Res 12:R47. 2010
    ..We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up...
  3. ncbi Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles
    Robert R Kitchen
    School of Physics, University of Edinburgh, 10 Crichton Street, Edinburgh, EH8 9AB, UK
    BMC Genomics 11:134. 2010
    ....
  4. ncbi Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project
    J Thomas
    Pathology Department, Western General Hospital and Breakthrough Breast Cancer Research Unit, Edinburgh EH4 2XU, UK
    Br J Cancer 102:285-93. 2010
    ..We have correlated these sizes with histological grade, specimen-handling methods, particularly the use of specimen slice radiographs, and the success or failure of breast-conserving surgery (BCS)...
  5. ncbi Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring
    J S J Thomas
    Pathology Department, Western General Hospital, Edinburgh, UK
    Histopathology 51:219-26. 2007
    ..Letrozole, an aromatase inhibitor, is used frequently in the treatment of oestrogen receptor-positive breast cancer. The aim was to examine the response patterns in a letrozole-treated group compared with a chemotherapy-treated group...
  6. ncbi Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project
    Jeremy Thomas
    Department of Pathology, Western General Hospital, Edinburgh, United Kingdom
    Breast J 14:33-8. 2008
    ..There are significant implications for the interpretation of clinical trials data in this area...
  7. ncbi Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up
    Jeremy St J Thomas
    Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
    Histopathology 55:724-31. 2009
    ....
  8. ncbi Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
    Matthew J Ellis
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Oncol 24:3019-25. 2006
    ....
  9. ncbi Is a radiotherapy boost truly beneficial?
    Alison Stillie
    Lancet Oncol 7:795-6; author reply 796-7. 2006
  10. ncbi Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial
    John M S Bartlett
    Endocrine Cancer Research Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
    J Clin Oncol 26:5027-35. 2008
    ..We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy...